ALEXANDRIA, VA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, founded in 1999, is a mid-sized nonprofit in the Medical Research sector that reported $39.1M in total revenue in fiscal year 2023. Revenue grew 18% year-over-year, indicating healthy expansion. Expenses of $33.6M left a modest 14% surplus.
CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY.
:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS &...
:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $190 MILLION TO SUPPORT GRANTS & AWARDS TO OVER 9,200 RECIPIENTS IN 89 COUNTRIES.HIGHLIGHTS OF 2023 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $1,350,000 PROVIDED THREE (3) THREE-YEAR AWARDS TO SUPPORT PHYSICIAN-SCIENTISTS COMMITTED TO PERFORMING ORIGINAL, CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. TWO AWARDS SUPPORTED DIVERSITY/INCLUSION, FOCUSING ON BREAST CANCER AND ONE AWARD FOCUSED ON TRIPLE-NEGATIVE BREAST CANCER.*CAREER DEVELOPMENT AWARD (CDA): $4,200,000 PROVIDED TWENTY-ONE (21) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS.*YOUNG INVESTIGATOR AWARD (YIA): $4,550,000 PROVIDED NINETY-ONE (91) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY PROVIDING FUNDS TO PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT.*GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $250,000 PROVIDED FIVE (5) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO ENCOURAGE AND PROMOTE QUALITY RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS.THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR.*INTERNATIONAL INNOVATION GRANT: $100,000 PROVIDED FIVE (5) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES OUR SKILLS AND EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE.
FUNDRAISING EXPENSE -201,634.
:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS...
:QUALITY & ACCESS TO CARE: REMARKABLE ADVANCES IN CANCER MEDICINE ARE OCCURRING MORE AND MORE FREQUENTLY, YET THE FULL PROMISE OF SUCH PROGRESS CANNOT BE REALIZED UNTIL HIGH QUALITY CANCER CARE IS AVAILABLE TO EVERYONE. CONQUER CANCER IS KEENLY AWARE OF THE POTENTIALLY FATAL DIVIDE BETWEEN THOSE WITH ACCESS TO THE FRUITS OF RESEARCH AND TIMELY CARE AND THOSE WITHOUT. WE SEEK TO CONFRONT THESE DISPARITIES AND IMPROVE THE OUTLOOK FOR EVERY PERSON TOUCHED BY CANCER BY SUPPORTING PROGRAMS THAT INCREASE ACCESS TO CARE IN ALL COMMUNITIES, INCLUDING THOSE UNDERSERVED.THROUGHOUT ASCO AND CONQUER CANCER'S HISTORY, THE ORGANIZATIONS HAVE STRIVED TO IMPROVE CARE FOR ALL PATIENTS WITH CANCER WHILE PAYING PARTICULAR ATTENTION TO THOSE MOST VULNERABLE. IN 2023, ASCO AND CONQUER CANCER CONTINUED WORK ON QUALITY AND EQUITABLE ACCESS TO CARE PROGRAMS THROUGH THEIR EQUITY, DIVERSITY AND INCLUSION INITIATIVE: ASCO AND CONQUER CANCER'S EQUITY, DIVERSITY AND INCLUSION INITIATIVE IS AMBITIOUS YET REALISTIC AND AIMS TO ADDRESS DISPARITIES AND WORK TOWARD ACHIEVING GREATER EQUITY IN CANCER CARE. PROGRAMS UNDER THIS INITIATIVE ADDRESS SUCH AREAS AS EDUCATION AND DIVERSIFICATION OF THE ONCOLOGY WORKFORCE AND SUPPORT FOR ONCOLOGISTS AND TRAINEES FROM UNDERREPRESENTED POPULATIONS IN MEDICINE; INCREASING PARTICIPATION BY DIVERSE POPULATIONS IN CLINICAL TRIALS; RESEARCH GRANTS IN DIVERSITY, INCLUSION, AND HEALTH DISPARITIES; PROVIDER TRAINING TO ADDRESS GAPS IN HEALTH DISPARITIES AND INCLUSION; AND ADDRESSING THE SPECIALIZED NEEDS OF POPULATIONS IN RURAL AREAS OF THE US.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $39,096,707 | $33,133,692 | +0.2% |
| Expenses | $33,575,680 | $32,888,928 | +0.0% |
| Net Income | $5,521,027 | $244,764 | +21.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| CLIFFORD A HUDIS MD | EXECUTIVE VICE CHAIR | 6.50 |
Officer
Director
|
$0 | $24,750 | $1,085,551 |
| HOWARD A BURRIS III MD | BOARD CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| AMY C PETERSON MD | SECRETARY | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ALEXANDER W CASDIN | TREASURER | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| KATHRYN BEAL | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| WILLIAM BEHNKE | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| RICCARDO BRAGLIA | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| OTIS BRAWLEY MD | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| LAWRENCE H EINHORN MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| RAJ MANTENA RPH | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| THOMAS A MARSLAND MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT J MAYER MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| GERALD J MCDOUGALL | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ANNE MOORE MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| W CHARLES PENLEY MD | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| THOMAS G ROBERTS JR MD | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| STEVEN T ROSEN MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ALEXANDRA SHAPIRO | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SANDRA SWAIN MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MARGARET A TEMPERO MD | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DEANNA B VAN GESTEL | BOARD MEMBER (PARTIAL YEAR) | 1.00 |
Director
|
$0 | $0 | $0 |
| LINDA JENSEN | CFO & EXECUTIVE VP | 1.00 |
Officer
|
$0 | $42,792 | $520,324 |
| NANCY DALY MS MPH | CEO & EXECUTIVE VP | 36.50 |
Officer
|
$0 | $42,677 | $559,314 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $39,096,707 | $33,575,680 | $110,051,603 | $5,521,027 |
| 2022 | $33,133,692 | $32,888,928 | $98,117,170 | $244,764 |
| 2021 | $24,641,302 | $28,405,556 | $109,850,269 | $-3,764,254 |
| 2020 | $33,042,638 | $25,241,608 | $107,923,414 | $7,801,030 |
| 2019 | $30,450,646 | $24,914,594 | $89,666,380 | $5,536,052 |
| 2018 | $33,166,990 | $23,884,739 | $74,547,914 | $9,282,251 |
Compare CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY with other nonprofits in Virginia and across the country.